1. The current status of biological treatment for uveitis
- Author
-
Jurgen Sota, Luca Cantarini, Valeria Caggiano, Salvatore Grosso, Stefano Gentileschi, Carla Gaggiano, Gian Marco Tosi, Bruno Frediani, and Claudia Fabiani
- Subjects
0301 basic medicine ,medicine.medical_specialty ,abatacept ,tumor necrosis factor inhibitors ,Immunology ,biosimilar drugs ,interleukin-1 inhibitors ,Treatment goals ,Antibodies, Monoclonal, Humanized ,Etanercept ,Uveitis ,03 medical and health sciences ,Infectious uveitis ,rituximab ,0302 clinical medicine ,Quality of life (healthcare) ,medicine ,Humans ,Immunology and Allergy ,steroid-sparing agents ,Intensive care medicine ,Social functioning ,030203 arthritis & rheumatology ,noninfectious uveitis ,Blindness ,Tumor Necrosis Factor-alpha ,business.industry ,uveitis biologic modifier agents ,Abatacept ,Adalimumab ,Antibodies, Monoclonal ,biotechnological therapy ,immunosuppressive treatment ,interferon ,interleukin-6 inhibitors ,JAK-inhibitors ,medicine.disease ,Infliximab ,030104 developmental biology ,Certolizumab Pegol ,Interferons ,business ,Developed country ,Interleukin-1 ,medicine.drug - Abstract
Noninfectious uveitis represents one of the leading causes of blindness in developed Countries, compromising patients' quality of life and social functioning. The main treatment goals are the control of ocular inflammation, to avert and treat sight-threatening complications, thus preserving and/or restoring visual function.This manuscript deals with systemic therapy with biologic drugs for noninfectious uveitis. An extensive literature search in the MEDLINE database (via PubMed) has been performed up to June 2020. The major classes of biologic molecules employed in ocular inflammatory diseases have been reviewed, focusing on TNF inhibitors, IL-1, IL-6, IL-17, IL-23 inhibitors, interferons, rituximab, and abatacept efficacy and safety. An overview of most recent developments in the field has been provided as well, with reference to the experience with JAK inhibitors and with biosimilar drugs.The development of the concept of targeted therapy and the subsequent introduction of biologic molecules in clinical practice have revolutionized the prognosis of uveitis. The target of a rapid and sustained steroid-free remission of ocular inflammation should be pursued for all patients early in the disease course, in order to have a better chance to improve the final visual outcome.
- Published
- 2020
- Full Text
- View/download PDF